These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 22855169)
1. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM). Madaan A; Singh P; Awasthi A; Verma R; Singh AT; Jaggi M; Mishra SK; Kulkarni S; Kulkarni H Clin Transl Oncol; 2013 Jan; 15(1):26-32. PubMed ID: 22855169 [TBL] [Abstract][Full Text] [Related]
2. Albumin-coated nanocrystals for carrier-free delivery of paclitaxel. Park J; Sun B; Yeo Y J Control Release; 2017 Oct; 263():90-101. PubMed ID: 28049022 [TBL] [Abstract][Full Text] [Related]
3. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978 [TBL] [Abstract][Full Text] [Related]
4. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ranade AA; Joshi DA; Phadke GK; Patil PP; Kasbekar RB; Apte TG; Dasare RR; Mengde SD; Parikh PM; Bhattacharyya GS; Lopes GL Ann Oncol; 2013 Sep; 24 Suppl 5():v6-12. PubMed ID: 23975704 [TBL] [Abstract][Full Text] [Related]
6. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. Wang F; Porter M; Konstantopoulos A; Zhang P; Cui H J Control Release; 2017 Dec; 267():100-118. PubMed ID: 28958854 [TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Feng Z; Zhao G; Yu L; Gough D; Howell SB Cancer Chemother Pharmacol; 2010 Apr; 65(5):923-30. PubMed ID: 19685054 [TBL] [Abstract][Full Text] [Related]
8. nab-Paclitaxel mechanisms of action and delivery. Yardley DA J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008 [TBL] [Abstract][Full Text] [Related]
9. Endosomal pH-Responsive Polymer-Based Dual-Ligand-Modified Micellar Nanoparticles for Tumor Targeted Delivery and Facilitated Intracellular Release of Paclitaxel. Gao Y; Zhang C; Zhou Y; Li J; Zhao L; Li Y; Liu Y; Li X Pharm Res; 2015 Aug; 32(8):2649-62. PubMed ID: 25676595 [TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Gawde KA; Sau S; Tatiparti K; Kashaw SK; Mehrmohammadi M; Azmi AS; Iyer AK Colloids Surf B Biointerfaces; 2018 Jul; 167():8-19. PubMed ID: 29625422 [TBL] [Abstract][Full Text] [Related]
11. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel. Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984 [TBL] [Abstract][Full Text] [Related]
12. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Karmali PP; Kotamraju VR; Kastantin M; Black M; Missirlis D; Tirrell M; Ruoslahti E Nanomedicine; 2009 Mar; 5(1):73-82. PubMed ID: 18829396 [TBL] [Abstract][Full Text] [Related]
13. Protein nanoparticles as drug carriers in clinical medicine. Hawkins MJ; Soon-Shiong P; Desai N Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779 [TBL] [Abstract][Full Text] [Related]
14. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176 [TBL] [Abstract][Full Text] [Related]
15. Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? Li C; Li Y; Gao Y; Wei N; Zhao X; Wang C; Li Y; Xiu X; Cui J Int J Pharm; 2014 Jul; 468(1-2):15-25. PubMed ID: 24709221 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment. Yu D; Li W; Zhang Y; Zhang B Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131 [TBL] [Abstract][Full Text] [Related]
17. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Xiao K; Luo J; Fowler WL; Li Y; Lee JS; Xing L; Cheng RH; Wang L; Lam KS Biomaterials; 2009 Oct; 30(30):6006-16. PubMed ID: 19660809 [TBL] [Abstract][Full Text] [Related]
18. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490 [TBL] [Abstract][Full Text] [Related]
19. Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System. Hama M; Ishima Y; Chuang VTG; Ando H; Shimizu T; Ishida T ACS Appl Mater Interfaces; 2021 May; 13(17):19736-19744. PubMed ID: 33881292 [TBL] [Abstract][Full Text] [Related]
20. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]